Novo Nordisk plans to resubmit an application to have Wegovy listed with ... for many Australians who could benefit from them, some form of government-funded access needs to be on the horizon.
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW ...
One of the most reliable forms of value investing is to look for companies that ... sit alongside a massive valuation discount to its Danish neighbour Novo Nordisk (DK:NOVO.B). The runaway valuations ...
Hosted on MSN22d
Why Novo Nordisk (NVO) Is Climbing TodayDanish weight-loss drug maker Novo Nordisk ... drug in pill form in the U.S. before its top rival in the weight loss category, Eli Lilly (LLY), does so. NVO expects to submit an application ...
Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
Despite strong Atlas growth, MongoDB must increase enterprise customer share to return to previous growth rates. See why I ...
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
The agency approved Novo Nordisk’s Ozempic to treat chronic kidney disease ... The agency granted priority review to Merck’s application for Welireg (belzutifan) for the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results